

RNS Number : 9659B
Avacta Group PLC
25 March 2025

Avacta Announces Completion of the Sale of Launch Diagnostics

LONDON AND PHILADELPHIA - 25 March 2025 - Further to the announcement made on 7 March 2025, Avacta Group plc (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that all closing conditions to the sale of the entire issued share capital of Launch Diagnostics Holdings Limited and its subsidiaries, its UK-headquartered and largest diagnostics unit, to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U, have been satisfied and completion of the sale took place yesterday.

-Ends-

For further information from Avacta, please contact:

Avacta Group plc

Michael Vinegrad, Group Communications
Director

<https://avacta.com/>

Peel Hunt (Nomad and Broker)

James Steel / Chris Golden

www.peelhunt.com

Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers

www.panmureliberum.com

ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Max
Bennett

avacta@icrhealthcare.com

Investor Contact

Renee Leck
THRUST Strategic Communications

renee@thrustsc.com

Media Contact

Carly Scaduto
Carly Scaduto Consulting

Carly@carlyscadutoconsulting.com

About Avacta - <https://avacta.com/>

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

About Palex Healthcare Group S.L.U - palexhealth.com

Palex is the European benchmark for advanced solutions in the healthcare sector, with over 70 years of experience providing tailored technological innovations to healthcare professionals and researchers. Its purpose is to improve lives by introducing cutting-edge technology to hospitals, laboratories, and research centers. Palex's approach ranges from selecting state-of-the-art products to offering technical support and specialized training for healthcare and research professionals. The company operates across various fields, including surgery, diagnostics, laboratory and critical care, ensuring solutions adapted to each client's needs. With a presence in multiple countries, Palex remains strongly committed to quality, innovation, and sustainability in the healthcare sector. Through its own brands and strategic partnerships with internationally renowned manufacturers, Palex positions itself as a key partner in the evolution of the medical-scientific sector, contributing to improved efficiency and safety in healthcare.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FURDDGDXSDDDGUS